Fengzhen Mo

623 total citations
22 papers, 490 citations indexed

About

Fengzhen Mo is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Fengzhen Mo has authored 22 papers receiving a total of 490 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Immunology, 11 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Fengzhen Mo's work include Immunotherapy and Immune Responses (13 papers), CAR-T cell therapy research (9 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Fengzhen Mo is often cited by papers focused on Immunotherapy and Immune Responses (13 papers), CAR-T cell therapy research (9 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Fengzhen Mo collaborates with scholars based in China, United States and Australia. Fengzhen Mo's co-authors include Xiaoling Lü, Xiaoqiong Hou, Zhuoran Tang, Xiaomei Yang, Aiqun Liu, Siliang Duan, Zixi Hu, Shihua Yin, Xiaomei Yang and Shenxia Xie and has published in prestigious journals such as Cancer Letters, Vaccine and Signal Transduction and Targeted Therapy.

In The Last Decade

Fengzhen Mo

21 papers receiving 489 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fengzhen Mo China 15 228 223 217 125 116 22 490
Xiaoqiong Hou China 12 188 0.8× 189 0.8× 166 0.8× 109 0.9× 91 0.8× 18 391
Emi A. Lutz United States 10 339 1.5× 481 2.2× 206 0.9× 124 1.0× 90 0.8× 12 687
Catherine Bessell United States 6 248 1.1× 267 1.2× 189 0.9× 143 1.1× 37 0.3× 7 490
Siliang Duan China 15 168 0.7× 206 0.9× 343 1.6× 216 1.7× 78 0.7× 29 645
Neeraja Dharmaraj United States 14 137 0.6× 314 1.4× 258 1.2× 97 0.8× 66 0.6× 20 604
Helena Villanueva Spain 15 226 1.0× 351 1.6× 532 2.5× 86 0.7× 116 1.0× 28 867
Simon Liang United States 5 279 1.2× 301 1.3× 221 1.0× 128 1.0× 40 0.3× 7 521
Mario Martínez Soldevilla Spain 11 116 0.5× 146 0.7× 476 2.2× 121 1.0× 53 0.5× 15 602
Victor Hernandez‐Gordillo United States 10 183 0.8× 65 0.3× 238 1.1× 185 1.5× 40 0.3× 11 570
Katrijn Broos Belgium 15 390 1.7× 384 1.7× 337 1.6× 66 0.5× 242 2.1× 20 771

Countries citing papers authored by Fengzhen Mo

Since Specialization
Citations

This map shows the geographic impact of Fengzhen Mo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fengzhen Mo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fengzhen Mo more than expected).

Fields of papers citing papers by Fengzhen Mo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fengzhen Mo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fengzhen Mo. The network helps show where Fengzhen Mo may publish in the future.

Co-authorship network of co-authors of Fengzhen Mo

This figure shows the co-authorship network connecting the top 25 collaborators of Fengzhen Mo. A scholar is included among the top collaborators of Fengzhen Mo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fengzhen Mo. Fengzhen Mo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Shilin, Wenxing Huang, Xiaomei Yang, et al.. (2025). Dendritic cell vaccines: Current research progress, challenges, and opportunities. Genes & Diseases. 13(4). 101913–101913.
2.
Liu, Jingzhou, Shuang Xiao, Yi Li, et al.. (2024). Adeno-Associated Virus Engineering and Load Strategy for Tropism Modification, Immune Evasion and Enhanced Transgene Expression. International Journal of Nanomedicine. Volume 19. 7691–7708. 11 indexed citations
3.
Sun, Shuyang, Bruce D. Hammock, Zhi Ping Xu, et al.. (2023). A dendritic/tumor fusion cell vaccine enhances efficacy of nanobody-based CAR-T cells against solid tumor. Theranostics. 13(14). 5099–5113. 16 indexed citations
4.
Sun, Shuyang, Xuan Wang, Xiaomei Yang, et al.. (2023). Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression. Journal of Hematology & Oncology. 16(1). 115–115. 16 indexed citations
5.
Shi, Wei, Xiaomei Yang, Shenxia Xie, et al.. (2021). A new PD-1-specific nanobody enhances the antitumor activity of T-cells in synergy with dendritic cell vaccine. Cancer Letters. 522. 184–197. 33 indexed citations
6.
Xie, Shenxia, Xiaoqiong Hou, Wei Yang, et al.. (2021). Endoglin-Aptamer-Functionalized Liposome-Equipped PD-1-Silenced T Cells Enhance Antitumoral Immunotherapeutic Effects. International Journal of Nanomedicine. Volume 16. 6017–6034. 8 indexed citations
7.
Mo, Fengzhen, Siliang Duan, Xiaobing Jiang, et al.. (2021). Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy. Signal Transduction and Targeted Therapy. 6(1). 80–80. 54 indexed citations
8.
Ding, Ziqiang, Dujin Wang, Wei Shi, et al.. (2020). <p>In vivo Targeting of Liver Cancer with Tissue- and Nuclei-Specific Mesoporous Silica Nanoparticle-Based Nanocarriers in mice</p>. International Journal of Nanomedicine. Volume 15. 8383–8400. 36 indexed citations
9.
Yang, Xiaomei, Shenxia Xie, Wei Shi, et al.. (2020). Single‐Domain Antibody‐Based TCR‐Like CAR‐T: A Potential Cancer Therapy. Journal of Immunology Research. 2020(1). 2454907–2454907. 14 indexed citations
10.
11.
Yang, Xiaofeng, Shenxia Xie, Xiaomei Yang, et al.. (2019). Opportunities and Challenges for Antibodies against Intracellular Antigens. Theranostics. 9(25). 7792–7806. 15 indexed citations
12.
Mo, Fengzhen, Siliang Duan, Aiqun Liu, et al.. (2019). Novel fusion cells derived from tumor cells expressing the heterologous α-galactose epitope and dendritic cells effectively target cancer. Vaccine. 37(7). 926–936. 7 indexed citations
13.
Yang, Xiaomei, Jing Zhao, Siliang Duan, et al.. (2019). Enhanced cytotoxic T lymphocytes recruitment targeting tumor vasculatures by endoglin aptamer and IP-10 plasmid presenting liposome-based nanocarriers. Theranostics. 9(14). 4066–4083. 28 indexed citations
14.
Yang, Xiaomei, Chunhui Lai, Aiqun Liu, et al.. (2019). Anti-Tumor Activity of Mannose-CpG-Oligodeoxynucleotides-Conjugated and Hepatoma Lysate-Loaded Nanoliposomes for Targeting Dendritic Cells In Vivo. Journal of Biomedical Nanotechnology. 15(5). 1018–1032. 22 indexed citations
15.
Wang, Wu, Xiaoqiong Hou, Xiaomei Yang, et al.. (2019). Highly sensitive detection of CTLA‑4‑positive T‑cell subgroups based on nanobody and fluorescent carbon quantum dots. Oncology Letters. 18(1). 109–116. 15 indexed citations
16.
Tang, Zhuoran, Fengzhen Mo, A. Q. Liu, et al.. (2019). A Nanobody Against Cytotoxic T-Lymphocyte Associated Antigen-4 Increases the Anti-Tumor Effects of Specific CD8+ T Cells. Journal of Biomedical Nanotechnology. 15(11). 2229–2239. 16 indexed citations
17.
Lai, Chunhui, Siliang Duan, Fang Ye, et al.. (2018). The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide. Theranostics. 8(6). 1723–1739. 80 indexed citations
18.
Li, Cui, Zhuoran Tang, Zixi Hu, et al.. (2018). Natural Single-Domain Antibody-Nanobody: A Novel Concept in the Antibody Field. Journal of Biomedical Nanotechnology. 14(1). 1–19. 31 indexed citations
19.
Liu, Aiqun, Xiaoqiong Hou, Zongqiang Lai, et al.. (2017). Screening and antitumor effect of an anti‑CTLA‑4 nanobody. Oncology Reports. 39(2). 511–518. 32 indexed citations
20.
Wang, Yiwei, Zixi Hu, Li Cui, et al.. (2017). The Research Progress of Artificial Antigen Presenting Cells. Journal of Nanoscience and Nanotechnology. 17(12). 8640–8653. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiaoqiong Hou Breakdown of academic impact, for papers by Emi A. Lutz Breakdown of academic impact, for papers by Catherine Bessell Breakdown of academic impact, for papers by Siliang Duan Breakdown of academic impact, for papers by Neeraja Dharmaraj Breakdown of academic impact, for papers by Helena Villanueva Breakdown of academic impact, for papers by Simon Liang Breakdown of academic impact, for papers by Mario Martínez Soldevilla Breakdown of academic impact, for papers by Victor Hernandez‐Gordillo Breakdown of academic impact, for papers by Katrijn Broos
Rankless by CCL
2026